JP5187862B2 - キノリン及びその治療的使用 - Google Patents
キノリン及びその治療的使用 Download PDFInfo
- Publication number
- JP5187862B2 JP5187862B2 JP2010501594A JP2010501594A JP5187862B2 JP 5187862 B2 JP5187862 B2 JP 5187862B2 JP 2010501594 A JP2010501594 A JP 2010501594A JP 2010501594 A JP2010501594 A JP 2010501594A JP 5187862 B2 JP5187862 B2 JP 5187862B2
- Authority
- JP
- Japan
- Prior art keywords
- acetic acid
- yloxy
- difluoromethoxy
- chloro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title description 8
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 244
- 125000005843 halogen group Chemical group 0.000 claims abstract description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 18
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 150000002367 halogens Chemical group 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 8
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- -1 R 3 is methylation Chemical group 0.000 claims description 129
- 150000003839 salts Chemical class 0.000 claims description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 229910052727 yttrium Inorganic materials 0.000 claims description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- CEKCIGRZJPGEKC-UHFFFAOYSA-N 2-[3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 CEKCIGRZJPGEKC-UHFFFAOYSA-N 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 3
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 3
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 claims description 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 3
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 3
- MIDBGOVWGDVRNU-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-8-fluoro-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 MIDBGOVWGDVRNU-UHFFFAOYSA-N 0.000 claims description 3
- MJYALLQJDQYLFR-UHFFFAOYSA-N 2-[2-cyclopropyl-8-fluoro-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound C1CC1C1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 MJYALLQJDQYLFR-UHFFFAOYSA-N 0.000 claims description 3
- WIBIYJCURGUTMM-UHFFFAOYSA-N 2-[3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 WIBIYJCURGUTMM-UHFFFAOYSA-N 0.000 claims description 3
- NJAXKCSTUNSYNH-UHFFFAOYSA-N 2-[3-[[4-(5-cyclopropyl-1,2-oxazol-4-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1C=1C=NOC=1C1CC1 NJAXKCSTUNSYNH-UHFFFAOYSA-N 0.000 claims description 3
- NOTBBHAOPMFKDI-UHFFFAOYSA-N 2-[3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 NOTBBHAOPMFKDI-UHFFFAOYSA-N 0.000 claims description 3
- BLDRWEHEHBTYLZ-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 BLDRWEHEHBTYLZ-UHFFFAOYSA-N 0.000 claims description 3
- XTUPBDFUFDYHGY-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(1-propan-2-ylpyrazol-3-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)N1C=CC(C=2C=CC(CC=3C(=NC4=C(Cl)C=CC(OCC(O)=O)=C4C=3C)OC(F)F)=CC=2)=N1 XTUPBDFUFDYHGY-UHFFFAOYSA-N 0.000 claims description 3
- VMCZZVGMOXKNMR-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(1-propan-2-ylpyrazol-4-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound C1=NN(C(C)C)C=C1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(O)=O)C=CC(Cl)=C2N=C1OC(F)F VMCZZVGMOXKNMR-UHFFFAOYSA-N 0.000 claims description 3
- PCEWINTZUHCGBM-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(1h-pyrazol-4-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1C=1C=NNC=1 PCEWINTZUHCGBM-UHFFFAOYSA-N 0.000 claims description 3
- WTKMJTZLSNPBHB-UHFFFAOYSA-N 2-[8-chloro-3-[[4-(3-chloropyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC(Cl)=N1 WTKMJTZLSNPBHB-UHFFFAOYSA-N 0.000 claims description 3
- GNZIHZXAFKMHEX-UHFFFAOYSA-N 2-[8-chloro-3-[[4-(4-chloropyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=C(Cl)C=N1 GNZIHZXAFKMHEX-UHFFFAOYSA-N 0.000 claims description 3
- VLYXMBYTYXIUPB-UHFFFAOYSA-N 2-[8-chloro-3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 VLYXMBYTYXIUPB-UHFFFAOYSA-N 0.000 claims description 3
- OHBBWGBMGOIGLQ-UHFFFAOYSA-N 2-[8-chloro-3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 OHBBWGBMGOIGLQ-UHFFFAOYSA-N 0.000 claims description 3
- TWYWHVLXPOESPV-UHFFFAOYSA-N 2-[8-fluoro-2-methoxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound COC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 TWYWHVLXPOESPV-UHFFFAOYSA-N 0.000 claims description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 150000002244 furazanes Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- QFAQJJQZCOULEH-INIZCTEOSA-N (2s)-2-[2-cyclopropyl-8-fluoro-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxypropanoic acid Chemical compound C=1C=C(N2N=CC=C2)C=CC=1CC=1C(C)=C2C(O[C@@H](C)C(O)=O)=CC=C(F)C2=NC=1C1CC1 QFAQJJQZCOULEH-INIZCTEOSA-N 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- YRMNURZYVIBDOY-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-8-fluoro-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 YRMNURZYVIBDOY-UHFFFAOYSA-N 0.000 claims description 2
- QBLZPVQTXZIGEN-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-8-fluoro-4-methyl-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC=CN1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(O)=O)C=CC(F)=C2N=C1OC(F)F QBLZPVQTXZIGEN-UHFFFAOYSA-N 0.000 claims description 2
- VATBPDAMEYECHM-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 VATBPDAMEYECHM-UHFFFAOYSA-N 0.000 claims description 2
- VPAUPWBPMXRBBX-UHFFFAOYSA-N 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC=CN1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(O)=O)C=CC(Cl)=C2N=C1OC(F)F VPAUPWBPMXRBBX-UHFFFAOYSA-N 0.000 claims description 2
- ALUOMCOECKYMKX-UHFFFAOYSA-N 2-[8-chloro-2-methoxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound COC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 ALUOMCOECKYMKX-UHFFFAOYSA-N 0.000 claims description 2
- KARGVHTTWQIJII-UHFFFAOYSA-N 2-[8-chloro-3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetic acid Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 KARGVHTTWQIJII-UHFFFAOYSA-N 0.000 claims description 2
- WFELTIRYFWESJZ-UHFFFAOYSA-N 2-[8-chloro-4-methyl-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]acetic acid Chemical compound CC(C)C1=NC2=C(Cl)C=CC(CC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 WFELTIRYFWESJZ-UHFFFAOYSA-N 0.000 claims description 2
- NACLEAFCWJZTFP-UHFFFAOYSA-N 2-[8-chloro-4-methyl-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 NACLEAFCWJZTFP-UHFFFAOYSA-N 0.000 claims description 2
- DFBVWPBNNOKBLF-UHFFFAOYSA-N 2-[8-fluoro-4-methyl-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC2=C(F)C=CC(OCC(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 DFBVWPBNNOKBLF-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims description 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract description 22
- 239000003446 ligand Substances 0.000 abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 description 280
- 238000002360 preparation method Methods 0.000 description 248
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 219
- 230000014759 maintenance of location Effects 0.000 description 171
- 239000000203 mixture Substances 0.000 description 170
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 88
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 88
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 68
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 65
- 238000005481 NMR spectroscopy Methods 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 51
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 44
- 235000019341 magnesium sulphate Nutrition 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 39
- 239000000284 extract Substances 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- 229920006395 saturated elastomer Polymers 0.000 description 35
- 238000010898 silica gel chromatography Methods 0.000 description 31
- 229960000583 acetic acid Drugs 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000011780 sodium chloride Substances 0.000 description 27
- 239000002904 solvent Substances 0.000 description 25
- 239000007787 solid Substances 0.000 description 24
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 21
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000012362 glacial acetic acid Substances 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 11
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 0 *C(C=CC(O)=CC1)=C1N Chemical compound *C(C=CC(O)=CC1)=C1N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- TXWDVWSJMDFNQY-UHFFFAOYSA-N 5-cyclopropyl-1h-pyrazole Chemical compound C1CC1C1=CC=NN1 TXWDVWSJMDFNQY-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- UDRCONFHWYGWFI-UHFFFAOYSA-N ethyl 3-oxopentanoate Chemical compound CCOC(=O)CC(=O)CC UDRCONFHWYGWFI-UHFFFAOYSA-N 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- FUOZJYASZOSONT-UHFFFAOYSA-N 2-propan-2-yl-1h-imidazole Chemical compound CC(C)C1=NC=CN1 FUOZJYASZOSONT-UHFFFAOYSA-N 0.000 description 4
- WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 4
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- CHMDGLGNZJCUMN-UHFFFAOYSA-N methyl 2-[3-[(4-bromophenyl)methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(Br)C=C1 CHMDGLGNZJCUMN-UHFFFAOYSA-N 0.000 description 4
- LQKRBPONSWMPEH-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1B1OC(C)(C)C(C)(C)O1 LQKRBPONSWMPEH-UHFFFAOYSA-N 0.000 description 4
- QYEMNJMSULGQRD-UHFFFAOYSA-N methyl-1H-quinolin-2-one Natural products C1=CC=C2C=CC(=O)N(C)C2=C1 QYEMNJMSULGQRD-UHFFFAOYSA-N 0.000 description 4
- CXOWCVAFSHLNGA-UHFFFAOYSA-N s-tert-butyl 2-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-3-oxobutanethioate Chemical compound CC(C)(C)SC(=O)C(C(=O)C)CC1=CC=C(C(=O)C(C)(C)C)C=C1 CXOWCVAFSHLNGA-UHFFFAOYSA-N 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- UQPDOAOTRQAZLP-UHFFFAOYSA-N tert-butyl 2-[3-[(4-bromophenyl)methyl]-8-chloro-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC1=CC=C(Br)C=C1 UQPDOAOTRQAZLP-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000011345 viscous material Substances 0.000 description 4
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 4
- VJCSFNNTQGRAKH-UHFFFAOYSA-N 3-amino-4-fluorophenol Chemical compound NC1=CC(O)=CC=C1F VJCSFNNTQGRAKH-UHFFFAOYSA-N 0.000 description 3
- CZJSEMZMYVIVKD-UHFFFAOYSA-N 4-bromo-5-cyclopropyl-1,2-oxazole Chemical compound C1=NOC(C2CC2)=C1Br CZJSEMZMYVIVKD-UHFFFAOYSA-N 0.000 description 3
- FHHRJUAWRYSTJL-UHFFFAOYSA-N 4-cyclopropyl-1h-pyrazole Chemical compound C1CC1C1=CNN=C1 FHHRJUAWRYSTJL-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- CSKXOMKNTKORFX-UHFFFAOYSA-N ethyl 2-[(4-acetylphenyl)methyl]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(C(C)=O)C=C1 CSKXOMKNTKORFX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- BNWMBAKERONWEE-UHFFFAOYSA-N methyl 2-(3-amino-4-chlorophenoxy)acetate Chemical compound COC(=O)COC1=CC=C(Cl)C(N)=C1 BNWMBAKERONWEE-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003653 radioligand binding assay Methods 0.000 description 3
- FXOMETKMHQLOHH-UHFFFAOYSA-N s-tert-butyl 3-oxobutanethioate Chemical compound CC(=O)CC(=O)SC(C)(C)C FXOMETKMHQLOHH-UHFFFAOYSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- PUZVEJOCLCFGMU-UHFFFAOYSA-N 1-(bromomethyl)-4-(2,2-dimethylpropyl)benzene Chemical compound CC(C)(C)CC1=CC=C(CBr)C=C1 PUZVEJOCLCFGMU-UHFFFAOYSA-N 0.000 description 2
- PHNRBSHOFSWNII-UHFFFAOYSA-N 1-[4-(bromomethyl)phenyl]pyrazole Chemical compound C1=CC(CBr)=CC=C1N1N=CC=C1 PHNRBSHOFSWNII-UHFFFAOYSA-N 0.000 description 2
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 2
- KNZYSURWHIRMFC-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-n-(2-chloro-5-hydroxyphenyl)-3-oxobutanamide Chemical compound C=1C(O)=CC=C(Cl)C=1NC(=O)C(C(=O)C)CC1=CC=C(Br)C=C1 KNZYSURWHIRMFC-UHFFFAOYSA-N 0.000 description 2
- QOWXMQZHPSICGI-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]-n-(2-fluoro-5-hydroxyphenyl)-3-oxobutanamide Chemical compound C=1C(O)=CC=C(F)C=1NC(=O)C(C(=O)C)CC1=CC=C(Br)C=C1 QOWXMQZHPSICGI-UHFFFAOYSA-N 0.000 description 2
- IJLAMIJVGKYAEL-UHFFFAOYSA-N 2-[3-[[4-(3-chloropyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC(Cl)=N1 IJLAMIJVGKYAEL-UHFFFAOYSA-N 0.000 description 2
- XIVWLEZFDUBICC-UHFFFAOYSA-N 2-[3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 XIVWLEZFDUBICC-UHFFFAOYSA-N 0.000 description 2
- KUEUXQQBZONLIC-UHFFFAOYSA-N 2-[3-[[4-(4-chloropyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=C(Cl)C=N1 KUEUXQQBZONLIC-UHFFFAOYSA-N 0.000 description 2
- YOZAOPSKXIEJCI-UHFFFAOYSA-N 2-[3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 YOZAOPSKXIEJCI-UHFFFAOYSA-N 0.000 description 2
- CYNZXBYIAYQKHG-UHFFFAOYSA-N 2-[3-[[4-(5-cyclopropyl-1,2-oxazol-4-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C=1C=NOC=1C1CC1 CYNZXBYIAYQKHG-UHFFFAOYSA-N 0.000 description 2
- UBRDQCSVSVZMDB-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[(4-pyrimidin-2-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=NC=CC=N1 UBRDQCSVSVZMDB-UHFFFAOYSA-N 0.000 description 2
- SVKSZLNBYRJTMX-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(1-methylimidazol-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=NC=CN1C SVKSZLNBYRJTMX-UHFFFAOYSA-N 0.000 description 2
- WGHBTAHTZALPOW-UHFFFAOYSA-N 2-[8-chloro-4-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-2-ethylquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 WGHBTAHTZALPOW-UHFFFAOYSA-N 0.000 description 2
- OKLRQYJIKDTJNM-UHFFFAOYSA-N 2-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-n-(2-fluoro-5-hydroxyphenyl)-3-oxobutanamide Chemical compound C=1C(O)=CC=C(F)C=1NC(=O)C(C(=O)C)CC1=CC=C(C(=O)C(C)(C)C)C=C1 OKLRQYJIKDTJNM-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- FZNOWRSVTYWZSB-UHFFFAOYSA-N 3-[(4-bromophenyl)methyl]-8-chloro-5-hydroxy-4-methyl-1h-quinolin-2-one Chemical compound O=C1NC2=C(Cl)C=CC(O)=C2C(C)=C1CC1=CC=C(Br)C=C1 FZNOWRSVTYWZSB-UHFFFAOYSA-N 0.000 description 2
- ZNIOLSUETNOGDB-UHFFFAOYSA-N 3-[(4-bromophenyl)methyl]-8-fluoro-5-hydroxy-4-methyl-1h-quinolin-2-one Chemical compound O=C1NC2=C(F)C=CC(O)=C2C(C)=C1CC1=CC=C(Br)C=C1 ZNIOLSUETNOGDB-UHFFFAOYSA-N 0.000 description 2
- FWUALUHYKLDYAN-UHFFFAOYSA-N 3-amino-4-chlorophenol Chemical compound NC1=CC(O)=CC=C1Cl FWUALUHYKLDYAN-UHFFFAOYSA-N 0.000 description 2
- BADSZRMNXWLUKO-UHFFFAOYSA-N 4-chloro-1h-pyrazole Chemical compound ClC=1C=NNC=1 BADSZRMNXWLUKO-UHFFFAOYSA-N 0.000 description 2
- IJPFBRONCJOTTA-UHFFFAOYSA-N 5-chloro-1h-pyrazole Chemical compound ClC1=CC=NN1 IJPFBRONCJOTTA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- ZHPFWTCBODKGKX-UHFFFAOYSA-N OC1=CC=CC2=C1C=CC(CC(C=C1)=CC=C1N1N=CC=C1)=N2 Chemical compound OC1=CC=CC2=C1C=CC(CC(C=C1)=CC=C1N1N=CC=C1)=N2 ZHPFWTCBODKGKX-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- VUVWSSVNLXVUFO-UHFFFAOYSA-N [4-[[4-(difluoromethoxy)-2-ethyl-8-fluoro-5-(2-methoxy-2-oxoethoxy)quinolin-3-yl]methyl]phenyl]boronic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(B(O)O)C=C1 VUVWSSVNLXVUFO-UHFFFAOYSA-N 0.000 description 2
- QIBPZVKOFWQWSQ-UHFFFAOYSA-N [chloro(difluoro)methyl] acetate Chemical compound CC(=O)OC(F)(F)Cl QIBPZVKOFWQWSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001638 boron Chemical class 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- HSGOTPMKJNSWFY-UHFFFAOYSA-N ethyl 2-[(4-bromophenyl)methyl]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(Br)C=C1 HSGOTPMKJNSWFY-UHFFFAOYSA-N 0.000 description 2
- NZLPLYGLFVYZFT-UHFFFAOYSA-N ethyl 2-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(C(=O)C(C)(C)C)C=C1 NZLPLYGLFVYZFT-UHFFFAOYSA-N 0.000 description 2
- HFTUXTOFBZUYIN-UHFFFAOYSA-N ethyl 3-oxo-2-[[4-(trifluoromethoxy)phenyl]methyl]pentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(OC(F)(F)F)C=C1 HFTUXTOFBZUYIN-UHFFFAOYSA-N 0.000 description 2
- UXFKVCQVMPHYRF-UHFFFAOYSA-N ethyl 4-methyl-3-oxo-2-[(4-pyrazol-1-ylphenyl)methyl]pentanoate Chemical compound C1=CC(CC(C(=O)OCC)C(=O)C(C)C)=CC=C1N1N=CC=C1 UXFKVCQVMPHYRF-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- IPULKOKYKIGVMW-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(NC(=O)OC(C)(C)C)C=C1 IPULKOKYKIGVMW-UHFFFAOYSA-N 0.000 description 2
- QBEUPYAWUGVTIQ-UHFFFAOYSA-N methyl 2-[8-chloro-4-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-2-ethylquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(Cl)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 QBEUPYAWUGVTIQ-UHFFFAOYSA-N 0.000 description 2
- VYZOLFMHWULKAC-UHFFFAOYSA-N methyl 2-[[2-ethyl-8-fluoro-3-[(4-methoxyphenyl)methyl]-4-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(F)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(OC)C=C1 VYZOLFMHWULKAC-UHFFFAOYSA-N 0.000 description 2
- WJGQNIMSTLORRF-UHFFFAOYSA-N methyl 2-[[3-[(4-acetylphenyl)methyl]-2-ethyl-8-fluoro-4-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(F)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(C(C)=O)C=C1 WJGQNIMSTLORRF-UHFFFAOYSA-N 0.000 description 2
- MODGXMUKHQASEI-UHFFFAOYSA-N methyl 2-[[3-[(4-bromophenyl)methyl]-2-ethyl-8-fluoro-4-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(F)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(Br)C=C1 MODGXMUKHQASEI-UHFFFAOYSA-N 0.000 description 2
- BBLVCFVPTQNBFJ-UHFFFAOYSA-N n-(2-chloro-5-hydroxyphenyl)-3-oxo-2-[(4-pyrazol-1-ylphenyl)methyl]butanamide Chemical compound C=1C(O)=CC=C(Cl)C=1NC(=O)C(C(=O)C)CC(C=C1)=CC=C1N1C=CC=N1 BBLVCFVPTQNBFJ-UHFFFAOYSA-N 0.000 description 2
- IUJNXRDWNJPSPF-UHFFFAOYSA-N n-(2-fluoro-5-hydroxyphenyl)-3-oxo-2-[(4-pyrazol-1-ylphenyl)methyl]butanamide Chemical compound C=1C(O)=CC=C(F)C=1NC(=O)C(C(=O)C)CC(C=C1)=CC=C1N1C=CC=N1 IUJNXRDWNJPSPF-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 2
- 229950004496 ramatroban Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- SZBBPYBQXSTVAT-UHFFFAOYSA-N s-tert-butyl 2-[(4-bromophenyl)methyl]-3-oxobutanethioate Chemical compound CC(C)(C)SC(=O)C(C(=O)C)CC1=CC=C(Br)C=C1 SZBBPYBQXSTVAT-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- GESWXNPJLZLWTR-UHFFFAOYSA-N tert-butyl 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1B1OC(C)(C)C(C)(C)O1 GESWXNPJLZLWTR-UHFFFAOYSA-N 0.000 description 2
- TYBQVORQJYXEHE-UHFFFAOYSA-N tert-butyl 2-[8-chloro-3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 TYBQVORQJYXEHE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Chemical class 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ZIDQIOZJEJFMOH-JKSUJKDBSA-N (3R,4S)-BW 245C Chemical compound C([C@@H](O)C1CCCCC1)CN1[C@@H](CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-JKSUJKDBSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UYFMSCHBODMWON-HBHIRWTLSA-N (z)-7-[(1s,2r,3r,4r)-3-[(e,3r)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H]2CC[C@H]1O2)C\C=C/CCCC(O)=O)OC1=CC=C(I)C=C1 UYFMSCHBODMWON-HBHIRWTLSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- GDIANGQCWOLCDB-UHFFFAOYSA-N 1,3-oxazol-2-ylstannane Chemical compound [SnH3]C1=NC=CO1 GDIANGQCWOLCDB-UHFFFAOYSA-N 0.000 description 1
- UOAIQCAHLUIZHW-UHFFFAOYSA-N 1-(bromomethyl)-4-(2-methylpropyl)benzene Chemical compound CC(C)CC1=CC=C(CBr)C=C1 UOAIQCAHLUIZHW-UHFFFAOYSA-N 0.000 description 1
- JDNPUJCKXLOHOW-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CBr)C=C1 JDNPUJCKXLOHOW-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LWGNAJWTBRYFJZ-UHFFFAOYSA-N 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC(C)N1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 LWGNAJWTBRYFJZ-UHFFFAOYSA-N 0.000 description 1
- KEZNMOUMHOZFRA-UHFFFAOYSA-N 1h-pyrazol-4-ylboronic acid Chemical compound OB(O)C=1C=NNC=1 KEZNMOUMHOZFRA-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-Dihydroxybenzoic acid Natural products OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- SRFASQKXNUOSHZ-UHFFFAOYSA-N 2-[3-[(4-acetylphenyl)methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(C(C)=O)C=C1 SRFASQKXNUOSHZ-UHFFFAOYSA-N 0.000 description 1
- VGCMFCBYAQDHTL-UHFFFAOYSA-N 2-[3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 VGCMFCBYAQDHTL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ADKPHUUIOUUTMH-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-3-[[4-(ethylsulfonylamino)phenyl]methyl]-8-fluoroquinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(NS(=O)(=O)CC)C=C1 ADKPHUUIOUUTMH-UHFFFAOYSA-N 0.000 description 1
- MJBYSLKWRCCSEQ-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[(4-methoxyphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(OC)C=C1 MJBYSLKWRCCSEQ-UHFFFAOYSA-N 0.000 description 1
- PUKHCPWRVXQTQD-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC=N1 PUKHCPWRVXQTQD-UHFFFAOYSA-N 0.000 description 1
- DSJLJVYGZNGZDF-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(1,3-oxazol-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=NC=CO1 DSJLJVYGZNGZDF-UHFFFAOYSA-N 0.000 description 1
- UCODDUWZTZFKGU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(1,3-thiazol-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=NC=CS1 UCODDUWZTZFKGU-UHFFFAOYSA-N 0.000 description 1
- XTDKAYRQMCFXAM-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(1-propan-2-ylpyrazol-3-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C=1C=CN(C(C)C)N=1 XTDKAYRQMCFXAM-UHFFFAOYSA-N 0.000 description 1
- GSXXPPBKHLWSPG-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CN=C1C(C)C GSXXPPBKHLWSPG-UHFFFAOYSA-N 0.000 description 1
- NSIQAXWDLJLCBE-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound FC(OC1=C(C(=NC2=C(C=CC(=C12)OCC(=O)O)F)CC)CC1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C)F NSIQAXWDLJLCBE-UHFFFAOYSA-N 0.000 description 1
- CNPOMZVPGVQYIN-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(trifluoromethoxy)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(OC(F)(F)F)C=C1 CNPOMZVPGVQYIN-UHFFFAOYSA-N 0.000 description 1
- LYVIYSTZIXRYBA-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-8-fluoro-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC2=C(F)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC=N1 LYVIYSTZIXRYBA-UHFFFAOYSA-N 0.000 description 1
- JUNIRRINVMBFQC-UHFFFAOYSA-N 2-[8-chloro-4-(difluoromethoxy)-2-ethyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC=N1 JUNIRRINVMBFQC-UHFFFAOYSA-N 0.000 description 1
- MOVBPHAJFDHDSZ-UHFFFAOYSA-N 2-[8-chloro-4-(difluoromethoxy)-2-ethyl-3-[[4-(2-methylpropanoyl)phenyl]methyl]quinolin-5-yl]oxyacetic acid Chemical compound CCC1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC1=CC=C(C(=O)C(C)C)C=C1 MOVBPHAJFDHDSZ-UHFFFAOYSA-N 0.000 description 1
- XCRMSTSHKAEACW-UHFFFAOYSA-N 2-[8-chloro-4-(difluoromethoxy)-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetic acid Chemical compound CC(C)C1=NC2=C(Cl)C=CC(OCC(O)=O)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC=N1 XCRMSTSHKAEACW-UHFFFAOYSA-N 0.000 description 1
- HRONSTBITYWQGP-UHFFFAOYSA-N 2-[[2-ethyl-8-fluoro-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]-1H-quinolin-5-yl]oxy]acetic acid Chemical compound C(C)C=1NC2=C(C=CC(=C2C(C=1CC1=CC=C(C=C1)OC(F)(F)F)=O)OCC(=O)O)F HRONSTBITYWQGP-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- SNFLIZHHADLFJJ-UHFFFAOYSA-N 2-chloro-8-fluoro-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-ol Chemical compound ClC1=NC2=C(F)C=CC(O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 SNFLIZHHADLFJJ-UHFFFAOYSA-N 0.000 description 1
- WZHKOXFRHZVLHB-UHFFFAOYSA-N 2-cyclopropyl-8-fluoro-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-ol Chemical compound C1CC1C1=NC2=C(F)C=CC(O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 WZHKOXFRHZVLHB-UHFFFAOYSA-N 0.000 description 1
- QKRMFCXDTFLKKT-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O QKRMFCXDTFLKKT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- SIIFNELEMHLBPY-UHFFFAOYSA-N 3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-8-fluoro-5-hydroxy-4-methyl-1h-quinolin-2-one Chemical compound O=C1NC2=C(F)C=CC(O)=C2C(C)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 SIIFNELEMHLBPY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- FWPJJQUPHVLVDM-UHFFFAOYSA-N 8-chloro-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-5-hydroxy-4-methyl-1h-quinolin-2-one Chemical compound O=C1NC2=C(Cl)C=CC(O)=C2C(C)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 FWPJJQUPHVLVDM-UHFFFAOYSA-N 0.000 description 1
- SYYPWTGDUPAXPD-UHFFFAOYSA-N 8-chloro-5-hydroxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-2-one Chemical compound O=C1NC2=C(Cl)C=CC(O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 SYYPWTGDUPAXPD-UHFFFAOYSA-N 0.000 description 1
- ZKNQWJXDWGAZDJ-UHFFFAOYSA-N 8-fluoro-4-methyl-2-prop-1-en-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-ol Chemical compound CC(=C)C1=NC2=C(F)C=CC(O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 ZKNQWJXDWGAZDJ-UHFFFAOYSA-N 0.000 description 1
- IJOHQJKQEZQFLI-UHFFFAOYSA-N 8-fluoro-5-hydroxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-2-one Chemical compound O=C1NC2=C(F)C=CC(O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 IJOHQJKQEZQFLI-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- RMENVFPYQMIBSU-UHFFFAOYSA-N CC(=O)C(CC1=CC=C(C=C1)Br)C(=O)S Chemical compound CC(=O)C(CC1=CC=C(C=C1)Br)C(=O)S RMENVFPYQMIBSU-UHFFFAOYSA-N 0.000 description 1
- DTWUPELRGZPIHN-UHFFFAOYSA-N CC(C(C(CC(C=C1)=CC=C1N1N=CC=C1)=C1C)=NC2=C1C(OP(O)(O)=O)=CC=C2Cl)=C Chemical compound CC(C(C(CC(C=C1)=CC=C1N1N=CC=C1)=C1C)=NC2=C1C(OP(O)(O)=O)=CC=C2Cl)=C DTWUPELRGZPIHN-UHFFFAOYSA-N 0.000 description 1
- YLMZPRDXEZBVGC-UHFFFAOYSA-N CC1=C(C(=O)NC2=C(C=CC(=C12)OCC(=O)O)Cl)CC3=CC=C(C=C3)Br Chemical compound CC1=C(C(=O)NC2=C(C=CC(=C12)OCC(=O)O)Cl)CC3=CC=C(C=C3)Br YLMZPRDXEZBVGC-UHFFFAOYSA-N 0.000 description 1
- KZJXKMSWCHSLGE-UHFFFAOYSA-N CC1=C(C(=O)NC2=C(C=CC(=C12)OCC(=O)O)F)CC3=CC=C(C=C3)Br Chemical compound CC1=C(C(=O)NC2=C(C=CC(=C12)OCC(=O)O)F)CC3=CC=C(C=C3)Br KZJXKMSWCHSLGE-UHFFFAOYSA-N 0.000 description 1
- FUZSMLULTCBOOC-UHFFFAOYSA-N CCC(=O)C(CC1=CC=C(C=C1)C(=O)C(C)C)C(=O)O Chemical compound CCC(=O)C(CC1=CC=C(C=C1)C(=O)C(C)C)C(=O)O FUZSMLULTCBOOC-UHFFFAOYSA-N 0.000 description 1
- VKYQNEIUVXEIPK-UHFFFAOYSA-N CCC(NC(C1=C(C=C2)OCC(O)=O)=C2Cl)=C(CC(C=C2)=CC=C2C(C(C)C)=O)C1=O Chemical compound CCC(NC(C1=C(C=C2)OCC(O)=O)=C2Cl)=C(CC(C=C2)=CC=C2C(C(C)C)=O)C1=O VKYQNEIUVXEIPK-UHFFFAOYSA-N 0.000 description 1
- LWRCRNQEYPCJSX-IBGZPJMESA-N C[C@@H](C(O)=O)Oc(c1c2nc(C3CC3)c(Cc(cc3)ccc3N3C(C)=C=CC=C3)c1C)ccc2F Chemical compound C[C@@H](C(O)=O)Oc(c1c2nc(C3CC3)c(Cc(cc3)ccc3N3C(C)=C=CC=C3)c1C)ccc2F LWRCRNQEYPCJSX-IBGZPJMESA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- SWJPBGYXOOCGQO-UHFFFAOYSA-N ClC1=C(C=C(C=C1)O)[N+](=O)[O-].COC(COC1=CC(=C(C=C1)Cl)[N+](=O)[O-])=O Chemical compound ClC1=C(C=C(C=C1)O)[N+](=O)[O-].COC(COC1=CC(=C(C=C1)Cl)[N+](=O)[O-])=O SWJPBGYXOOCGQO-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- JQVWMGFFGFPGTK-UHFFFAOYSA-N NC=1C=C(C=CC1F)O.COC(COC1=CC(=C(C=C1)F)N)=O Chemical compound NC=1C=C(C=CC1F)O.COC(COC1=CC(=C(C=C1)F)N)=O JQVWMGFFGFPGTK-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- HTAFGHHWQKEOSY-UHFFFAOYSA-N [8-fluoro-4-methyl-2-oxo-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl] dihydrogen phosphate Chemical compound O=C1NC2=C(F)C=CC(OP(O)(O)=O)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC=N1 HTAFGHHWQKEOSY-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- XLVFMHJIPJCRIU-UHFFFAOYSA-N butyl-(1-methoxyethenoxy)-dimethylsilane Chemical compound CCCC[Si](C)(C)OC(=C)OC XLVFMHJIPJCRIU-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical group 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- NNSSZDGDPANXJJ-UHFFFAOYSA-N ethyl 2-[(4-methoxyphenyl)methyl]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(OC)C=C1 NNSSZDGDPANXJJ-UHFFFAOYSA-N 0.000 description 1
- NNVIVCUEGPKROE-UHFFFAOYSA-N ethyl 2-[[4-(2-methylpropanoyl)phenyl]methyl]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)CC)CC1=CC=C(C(=O)C(C)C)C=C1 NNVIVCUEGPKROE-UHFFFAOYSA-N 0.000 description 1
- KSPHKPHNWFNHHK-UHFFFAOYSA-N ethyl 3-oxo-2-[(4-pyrazol-1-ylphenyl)methyl]pentanoate Chemical compound C1=CC(CC(C(=O)OCC)C(=O)CC)=CC=C1N1N=CC=C1 KSPHKPHNWFNHHK-UHFFFAOYSA-N 0.000 description 1
- XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 125000000468 ketone group Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- JLEJCNOTNLZCHQ-GSVOUGTGSA-N methyl (2r)-2-chloropropanoate Chemical compound COC(=O)[C@@H](C)Cl JLEJCNOTNLZCHQ-GSVOUGTGSA-N 0.000 description 1
- HVYFTFXJZQQMFQ-UHFFFAOYSA-N methyl 2-[2-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound CC1=C2C(OCC(=O)OC)=CC=C(F)C2=NC(OC(F)F)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 HVYFTFXJZQQMFQ-UHFFFAOYSA-N 0.000 description 1
- PJXMKQLSHYKRDZ-UHFFFAOYSA-N methyl 2-[3-[(4-acetylphenyl)methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(C(C)=O)C=C1 PJXMKQLSHYKRDZ-UHFFFAOYSA-N 0.000 description 1
- WMIIRAGAOHFHNG-UHFFFAOYSA-N methyl 2-[3-[(4-aminophenyl)methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(N)C=C1 WMIIRAGAOHFHNG-UHFFFAOYSA-N 0.000 description 1
- LPDQGCPUIXTSHF-UHFFFAOYSA-N methyl 2-[3-[[4-(3-chloropyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC(Cl)=N1 LPDQGCPUIXTSHF-UHFFFAOYSA-N 0.000 description 1
- ITWZJMSZRYSZQX-UHFFFAOYSA-N methyl 2-[3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 ITWZJMSZRYSZQX-UHFFFAOYSA-N 0.000 description 1
- QVABEFDFNGVLAE-UHFFFAOYSA-N methyl 2-[3-[[4-(4-chloropyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=C(Cl)C=N1 QVABEFDFNGVLAE-UHFFFAOYSA-N 0.000 description 1
- JBYSWWSTLSGZGW-UHFFFAOYSA-N methyl 2-[3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 JBYSWWSTLSGZGW-UHFFFAOYSA-N 0.000 description 1
- OYCCAVJMNYLSEF-UHFFFAOYSA-N methyl 2-[3-[[4-(5-cyclopropyl-1,2-oxazol-4-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C=1C=NOC=1C1CC1 OYCCAVJMNYLSEF-UHFFFAOYSA-N 0.000 description 1
- MWJFAUBQRLCVEN-UHFFFAOYSA-N methyl 2-[3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-4-(difluoromethoxy)-2-ethyl-8-fluoroquinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 MWJFAUBQRLCVEN-UHFFFAOYSA-N 0.000 description 1
- DBZISZZXNJVGKT-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[(4-methoxyphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(OC)C=C1 DBZISZZXNJVGKT-UHFFFAOYSA-N 0.000 description 1
- BQQIYHFQJBAQEB-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(1-methylimidazol-2-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=NC=CN1C BQQIYHFQJBAQEB-UHFFFAOYSA-N 0.000 description 1
- CVGDSYVSKPLFKG-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-2-ethyl-8-fluoro-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(F)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CN=C1C(C)C CVGDSYVSKPLFKG-UHFFFAOYSA-N 0.000 description 1
- YZUPSVTXZBWUJZ-UHFFFAOYSA-N methyl 2-[4-(difluoromethoxy)-8-fluoro-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=C2C(OCC(=O)OC)=CC=C(F)C2=NC(C(C)C)=C1CC(C=C1)=CC=C1N1C=CC=N1 YZUPSVTXZBWUJZ-UHFFFAOYSA-N 0.000 description 1
- ZIFWPBZJYMFVSV-UHFFFAOYSA-N methyl 2-[8-chloro-2-(difluoromethoxy)-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-4-methylquinolin-5-yl]oxyacetate Chemical compound CC1=C2C(OCC(=O)OC)=CC=C(Cl)C2=NC(OC(F)F)=C1CC1=CC=C(C(=O)C(C)(C)C)C=C1 ZIFWPBZJYMFVSV-UHFFFAOYSA-N 0.000 description 1
- VKIFBDUIOOYBFI-UHFFFAOYSA-N methyl 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound CC1=C2C(OCC(=O)OC)=CC=C(Cl)C2=NC(OC(F)F)=C1CC(C=C1)=CC=C1N1C=CC=N1 VKIFBDUIOOYBFI-UHFFFAOYSA-N 0.000 description 1
- BHFTYALYXUOYML-UHFFFAOYSA-N methyl 2-[8-chloro-4-(difluoromethoxy)-2-ethyl-3-[[4-(2-methylpropanoyl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CCC1=NC2=C(Cl)C=CC(OCC(=O)OC)=C2C(OC(F)F)=C1CC1=CC=C(C(=O)C(C)C)C=C1 BHFTYALYXUOYML-UHFFFAOYSA-N 0.000 description 1
- MJIFMIZIYIGBLE-UHFFFAOYSA-N methyl 2-[8-chloro-4-(difluoromethoxy)-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=C2C(OCC(=O)OC)=CC=C(Cl)C2=NC(C(C)C)=C1CC(C=C1)=CC=C1N1C=CC=N1 MJIFMIZIYIGBLE-UHFFFAOYSA-N 0.000 description 1
- KSUVDFLHUXKARV-UHFFFAOYSA-N methyl 2-[8-chloro-4-methyl-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound CC1=C2C(OCC(=O)OC)=CC=C(Cl)C2=NC(C(C)C)=C1CC(C=C1)=CC=C1N1C=CC=N1 KSUVDFLHUXKARV-UHFFFAOYSA-N 0.000 description 1
- FSQBAZFGNQPDAS-UHFFFAOYSA-N methyl 2-[8-fluoro-2-methoxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]quinolin-5-yl]oxyacetate Chemical compound CC1=C2C(OCC(=O)OC)=CC=C(F)C2=NC(OC)=C1CC(C=C1)=CC=C1N1C=CC=N1 FSQBAZFGNQPDAS-UHFFFAOYSA-N 0.000 description 1
- RWJOKVIPDWSFBE-UHFFFAOYSA-N methyl 2-[[2-ethyl-8-fluoro-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(F)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(OC(F)(F)F)C=C1 RWJOKVIPDWSFBE-UHFFFAOYSA-N 0.000 description 1
- IYFGEHDUQQWQPW-UHFFFAOYSA-N methyl 2-[[3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-8-fluoro-4-methyl-2-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CC=1C=2C(OCC(=O)OC)=CC=C(F)C=2NC(=O)C=1CC1=CC=C(C(=O)C(C)(C)C)C=C1 IYFGEHDUQQWQPW-UHFFFAOYSA-N 0.000 description 1
- BUMYUNUHMZBVBO-UHFFFAOYSA-N methyl 2-[[8-chloro-2-ethyl-3-[[4-(2-methylpropanoyl)phenyl]methyl]-4-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(Cl)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(C(=O)C(C)C)C=C1 BUMYUNUHMZBVBO-UHFFFAOYSA-N 0.000 description 1
- VTJBQOLCGIQVJA-UHFFFAOYSA-N methyl 2-[[8-chloro-2-ethyl-4-oxo-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(Cl)C=CC(OCC(=O)OC)=C2C(=O)C=1CC(C=C1)=CC=C1N1C=CC=N1 VTJBQOLCGIQVJA-UHFFFAOYSA-N 0.000 description 1
- YQPXFYTYPRFKIA-UHFFFAOYSA-N methyl 2-[[8-chloro-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-2-ethyl-4-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CCC=1NC2=C(Cl)C=CC(OCC(=O)OC)=C2C(=O)C=1CC1=CC=C(C(=O)C(C)(C)C)C=C1 YQPXFYTYPRFKIA-UHFFFAOYSA-N 0.000 description 1
- KRSFNNMJIMQCOR-UHFFFAOYSA-N methyl 2-[[8-chloro-3-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-4-methyl-2-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound CC=1C=2C(OCC(=O)OC)=CC=C(Cl)C=2NC(=O)C=1CC1=CC=C(C(=O)C(C)(C)C)C=C1 KRSFNNMJIMQCOR-UHFFFAOYSA-N 0.000 description 1
- XYWZQLNSJMKBNJ-UHFFFAOYSA-N methyl 2-[[8-chloro-4-methyl-2-oxo-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound CC=1C=2C(OCC(=O)OC)=CC=C(Cl)C=2NC(=O)C=1CC(C=C1)=CC=C1N1C=CC=N1 XYWZQLNSJMKBNJ-UHFFFAOYSA-N 0.000 description 1
- XXOJXURXLCLYCU-UHFFFAOYSA-N methyl 2-[[8-chloro-4-oxo-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound O=C1C=2C(OCC(=O)OC)=CC=C(Cl)C=2NC(C(C)C)=C1CC(C=C1)=CC=C1N1C=CC=N1 XXOJXURXLCLYCU-UHFFFAOYSA-N 0.000 description 1
- DERGXVGBSGIFJF-UHFFFAOYSA-N methyl 2-[[8-fluoro-4-methyl-2-oxo-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound CC=1C=2C(OCC(=O)OC)=CC=C(F)C=2NC(=O)C=1CC(C=C1)=CC=C1N1C=CC=N1 DERGXVGBSGIFJF-UHFFFAOYSA-N 0.000 description 1
- XVVUUXSTLQGWKE-UHFFFAOYSA-N methyl 2-[[8-fluoro-4-oxo-2-propan-2-yl-3-[(4-pyrazol-1-ylphenyl)methyl]-1h-quinolin-5-yl]oxy]acetate Chemical compound O=C1C=2C(OCC(=O)OC)=CC=C(F)C=2NC(C(C)C)=C1CC(C=C1)=CC=C1N1C=CC=N1 XVVUUXSTLQGWKE-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- SFILLZOAJGLFHB-UHFFFAOYSA-N n-(2-chloro-5-hydroxyphenyl)-2-[[4-(2,2-dimethylpropanoyl)phenyl]methyl]-3-oxobutanamide Chemical compound C=1C(O)=CC=C(Cl)C=1NC(=O)C(C(=O)C)CC1=CC=C(C(=O)C(C)(C)C)C=C1 SFILLZOAJGLFHB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000020469 nerve plexus disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 150000002941 palladium compounds Chemical class 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 201000006380 plexopathy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 150000003151 propanoic acid esters Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- ZQXIYGFVDOOUHI-UHFFFAOYSA-N s-tert-butyl 3-oxo-2-[(4-pyrazol-1-ylphenyl)methyl]butanethioate Chemical compound C1=CC(CC(C(=O)C)C(=O)SC(C)(C)C)=CC=C1N1N=CC=C1 ZQXIYGFVDOOUHI-UHFFFAOYSA-N 0.000 description 1
- BVMZYBZGPGIIQF-UHFFFAOYSA-N s-tert-butyl butanethioate Chemical compound CCCC(=O)SC(C)(C)C BVMZYBZGPGIIQF-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229910052710 silicon Chemical group 0.000 description 1
- 239000010703 silicon Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- KZJPVUDYAMEDRM-UHFFFAOYSA-M silver;2,2,2-trifluoroacetate Chemical compound [Ag+].[O-]C(=O)C(F)(F)F KZJPVUDYAMEDRM-UHFFFAOYSA-M 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- VXIWFIHUPSREOQ-UHFFFAOYSA-N tert-butyl 2-[2-(difluoromethoxy)-8-fluoro-4-methyl-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CC(C)C1=NC=CN1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(=O)OC(C)(C)C)C=CC(F)=C2N=C1OC(F)F VXIWFIHUPSREOQ-UHFFFAOYSA-N 0.000 description 1
- RVOQAQNEPCQEQI-UHFFFAOYSA-N tert-butyl 2-[3-[(4-bromophenyl)methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC1=CC=C(Br)C=C1 RVOQAQNEPCQEQI-UHFFFAOYSA-N 0.000 description 1
- JJQRXDVASXAPOI-UHFFFAOYSA-N tert-butyl 2-[3-[[4-(3-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N(N=1)C=CC=1C1CC1 JJQRXDVASXAPOI-UHFFFAOYSA-N 0.000 description 1
- ODMBWNCJVOTQHV-UHFFFAOYSA-N tert-butyl 2-[3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 ODMBWNCJVOTQHV-UHFFFAOYSA-N 0.000 description 1
- CYEOUXFSLXUDBT-UHFFFAOYSA-N tert-butyl 2-[3-[[4-(5-cyclopropyl-1,2-oxazol-4-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1C=1C=NOC=1C1CC1 CYEOUXFSLXUDBT-UHFFFAOYSA-N 0.000 description 1
- IQESXJCCEALKOO-UHFFFAOYSA-N tert-butyl 2-[3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-8-fluoro-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 IQESXJCCEALKOO-UHFFFAOYSA-N 0.000 description 1
- RPARJJPAHUTEMS-UHFFFAOYSA-N tert-butyl 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(1-propan-2-ylpyrazol-3-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CC(C)N1C=CC(C=2C=CC(CC=3C(=NC4=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C4C=3C)OC(F)F)=CC=2)=N1 RPARJJPAHUTEMS-UHFFFAOYSA-N 0.000 description 1
- BMTVGIZPIWTQGY-UHFFFAOYSA-N tert-butyl 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(1-propan-2-ylpyrazol-4-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound C1=NN(C(C)C)C=C1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(=O)OC(C)(C)C)C=CC(Cl)=C2N=C1OC(F)F BMTVGIZPIWTQGY-UHFFFAOYSA-N 0.000 description 1
- LSEHBXQMPXDHKX-UHFFFAOYSA-N tert-butyl 2-[8-chloro-2-(difluoromethoxy)-4-methyl-3-[[4-(2-propan-2-ylimidazol-1-yl)phenyl]methyl]quinolin-5-yl]oxyacetate Chemical compound CC(C)C1=NC=CN1C(C=C1)=CC=C1CC1=C(C)C2=C(OCC(=O)OC(C)(C)C)C=CC(Cl)=C2N=C1OC(F)F LSEHBXQMPXDHKX-UHFFFAOYSA-N 0.000 description 1
- BJPMGZGXSAQOAK-UHFFFAOYSA-N tert-butyl 2-[8-chloro-3-[[4-(3-chloropyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N1C=CC(Cl)=N1 BJPMGZGXSAQOAK-UHFFFAOYSA-N 0.000 description 1
- WRNIAGYUTHHCJP-UHFFFAOYSA-N tert-butyl 2-[8-chloro-3-[[4-(4-chloropyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N1C=C(Cl)C=N1 WRNIAGYUTHHCJP-UHFFFAOYSA-N 0.000 description 1
- ZHOMIPQWOPPLQC-UHFFFAOYSA-N tert-butyl 2-[8-chloro-3-[[4-(4-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N(N=C1)C=C1C1CC1 ZHOMIPQWOPPLQC-UHFFFAOYSA-N 0.000 description 1
- IIBUWJARKIYCNM-UHFFFAOYSA-N tert-butyl 2-[8-chloro-3-[[4-(5-cyclopropylpyrazol-1-yl)phenyl]methyl]-2-(difluoromethoxy)-4-methylquinolin-5-yl]oxyacetate Chemical compound FC(F)OC1=NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC(C=C1)=CC=C1N1N=CC=C1C1CC1 IIBUWJARKIYCNM-UHFFFAOYSA-N 0.000 description 1
- RCWPRNHTMVARPN-UHFFFAOYSA-N tert-butyl 2-[[3-[(4-bromophenyl)methyl]-8-chloro-4-methyl-2-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound O=C1NC2=C(Cl)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC1=CC=C(Br)C=C1 RCWPRNHTMVARPN-UHFFFAOYSA-N 0.000 description 1
- HECOUEUWXGGKDG-UHFFFAOYSA-N tert-butyl 2-[[3-[(4-bromophenyl)methyl]-8-fluoro-4-methyl-2-oxo-1h-quinolin-5-yl]oxy]acetate Chemical compound O=C1NC2=C(F)C=CC(OCC(=O)OC(C)(C)C)=C2C(C)=C1CC1=CC=C(Br)C=C1 HECOUEUWXGGKDG-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- KFWFYOPKNSYTMV-UHFFFAOYSA-N tributyl-(1-methylimidazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CN1C KFWFYOPKNSYTMV-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0706636.8 | 2007-04-04 | ||
GB0706636A GB0706636D0 (en) | 2007-04-04 | 2007-04-04 | Receptor ligands |
GB0724430.4 | 2007-12-14 | ||
GB0724430A GB0724430D0 (en) | 2007-12-14 | 2007-12-14 | Receptor ligands |
PCT/GB2008/001201 WO2008122784A1 (en) | 2007-04-04 | 2008-04-03 | Quinolines and their therapeutic use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010523537A JP2010523537A (ja) | 2010-07-15 |
JP5187862B2 true JP5187862B2 (ja) | 2013-04-24 |
Family
ID=39561800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010501594A Expired - Fee Related JP5187862B2 (ja) | 2007-04-04 | 2008-04-03 | キノリン及びその治療的使用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8173812B2 (es) |
EP (1) | EP2139881B1 (es) |
JP (1) | JP5187862B2 (es) |
CN (1) | CN101679359B (es) |
AT (1) | ATE532780T1 (es) |
AU (1) | AU2008235282B2 (es) |
BR (1) | BRPI0809983A2 (es) |
CA (1) | CA2680682C (es) |
CY (1) | CY1112679T1 (es) |
DK (1) | DK2139881T3 (es) |
EA (1) | EA017093B1 (es) |
ES (1) | ES2375588T3 (es) |
HK (1) | HK1142604A1 (es) |
HR (1) | HRP20110987T1 (es) |
IL (1) | IL201013A (es) |
MX (1) | MX2009010461A (es) |
NZ (1) | NZ579659A (es) |
PL (1) | PL2139881T3 (es) |
PT (1) | PT2139881E (es) |
SI (1) | SI2139881T1 (es) |
WO (1) | WO2008122784A1 (es) |
ZA (1) | ZA200906384B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173812B2 (en) * | 2007-04-04 | 2012-05-08 | Pulmagen Therapeutics (Asthma) Limited | Quinolines and their therapeutic use |
DE602008005796D1 (de) | 2007-12-14 | 2011-05-05 | Pulmagen Therapeutics Asthma Ltd | Indole und ihre therapeutische verwendung |
RU2013104506A (ru) * | 2010-07-05 | 2014-08-10 | Актелион Фармасьютиклз Лтд | 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
RU2014129613A (ru) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2 |
US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
TW201416354A (zh) * | 2012-07-17 | 2014-05-01 | Boehringer Ingelheim Int | 白三烯生成抑制劑 |
EP3492919A3 (en) | 2014-02-24 | 2019-07-10 | Ventana Medical Systems, Inc. | Quinone methide analog signal amplification |
WO2022175829A1 (en) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58225065A (ja) * | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | 2−キノロン誘導体 |
TW297025B (es) * | 1992-02-14 | 1997-02-01 | Squibb & Sons Inc | |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
BRPI0616452B8 (pt) * | 2005-09-30 | 2021-05-25 | Argenta Discovery Ltd | quinolinas e seu uso terapêutico |
US8173812B2 (en) * | 2007-04-04 | 2012-05-08 | Pulmagen Therapeutics (Asthma) Limited | Quinolines and their therapeutic use |
-
2008
- 2008-04-03 US US12/531,935 patent/US8173812B2/en not_active Expired - Fee Related
- 2008-04-03 SI SI200830512T patent/SI2139881T1/sl unknown
- 2008-04-03 CN CN2008800110606A patent/CN101679359B/zh not_active Expired - Fee Related
- 2008-04-03 NZ NZ579659A patent/NZ579659A/en not_active IP Right Cessation
- 2008-04-03 PL PL08736891T patent/PL2139881T3/pl unknown
- 2008-04-03 EP EP08736891A patent/EP2139881B1/en not_active Not-in-force
- 2008-04-03 DK DK08736891.6T patent/DK2139881T3/da active
- 2008-04-03 AT AT08736891T patent/ATE532780T1/de active
- 2008-04-03 WO PCT/GB2008/001201 patent/WO2008122784A1/en active Application Filing
- 2008-04-03 CA CA2680682A patent/CA2680682C/en not_active Expired - Fee Related
- 2008-04-03 JP JP2010501594A patent/JP5187862B2/ja not_active Expired - Fee Related
- 2008-04-03 AU AU2008235282A patent/AU2008235282B2/en not_active Ceased
- 2008-04-03 ES ES08736891T patent/ES2375588T3/es active Active
- 2008-04-03 PT PT08736891T patent/PT2139881E/pt unknown
- 2008-04-03 EA EA200970911A patent/EA017093B1/ru not_active IP Right Cessation
- 2008-04-03 MX MX2009010461A patent/MX2009010461A/es active IP Right Grant
- 2008-04-03 BR BRPI0809983-9A2A patent/BRPI0809983A2/pt not_active Application Discontinuation
-
2009
- 2009-09-14 ZA ZA2009/06384A patent/ZA200906384B/en unknown
- 2009-09-17 IL IL201013A patent/IL201013A/en active IP Right Grant
-
2010
- 2010-09-24 HK HK10109142.6A patent/HK1142604A1/xx not_active IP Right Cessation
-
2011
- 2011-12-30 HR HR20110987T patent/HRP20110987T1/hr unknown
-
2012
- 2012-01-17 CY CY20121100048T patent/CY1112679T1/el unknown
- 2012-03-30 US US13/435,242 patent/US8394830B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EA200970911A1 (ru) | 2010-04-30 |
IL201013A0 (en) | 2010-05-17 |
DK2139881T3 (da) | 2012-01-30 |
CY1112679T1 (el) | 2016-02-10 |
US20120184579A1 (en) | 2012-07-19 |
BRPI0809983A2 (pt) | 2014-10-14 |
AU2008235282A1 (en) | 2008-10-16 |
MX2009010461A (es) | 2010-02-18 |
EP2139881B1 (en) | 2011-11-09 |
CA2680682A1 (en) | 2008-10-16 |
US20100144787A1 (en) | 2010-06-10 |
PL2139881T3 (pl) | 2012-04-30 |
CA2680682C (en) | 2015-05-26 |
PT2139881E (pt) | 2012-01-17 |
CN101679359A (zh) | 2010-03-24 |
ES2375588T3 (es) | 2012-03-02 |
US8394830B2 (en) | 2013-03-12 |
WO2008122784A1 (en) | 2008-10-16 |
US8173812B2 (en) | 2012-05-08 |
IL201013A (en) | 2015-01-29 |
EP2139881A1 (en) | 2010-01-06 |
EA017093B1 (ru) | 2012-09-28 |
ZA200906384B (en) | 2010-11-24 |
HRP20110987T1 (hr) | 2012-01-31 |
JP2010523537A (ja) | 2010-07-15 |
CN101679359B (zh) | 2013-03-06 |
SI2139881T1 (sl) | 2012-05-31 |
AU2008235282A8 (en) | 2009-11-26 |
NZ579659A (en) | 2012-01-12 |
AU2008235282B2 (en) | 2011-02-24 |
ATE532780T1 (de) | 2011-11-15 |
HK1142604A1 (en) | 2010-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5187862B2 (ja) | キノリン及びその治療的使用 | |
US10590118B2 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
TWI649325B (zh) | 用於治療囊狀纖維化之新穎化合物及其醫藥組合物 | |
EP2327693B9 (en) | Indoles and their therapeutic use | |
JP4990285B2 (ja) | キノリンおよびその治療的使用 | |
JP6820836B2 (ja) | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体 | |
US20170128437A1 (en) | Amino-quinolines as kinase inhibitors | |
US20100093751A1 (en) | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | |
EP2129661B1 (en) | Quinoline derivatives as crth2 receptor ligands | |
JP2011509985A (ja) | Crth2受容体に対して活性なインドール | |
WO2010142934A1 (en) | Indole derivatives as ligands of crth2 receptors | |
TW200524620A (en) | Amide derivatives | |
US9796726B2 (en) | Dihydroquinoline pyrazolyl compounds | |
US9790200B2 (en) | Dihydroquinoline pyrazolyl compounds | |
NZ580310A (en) | Quinoline derivatives as crth2 receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130117 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5187862 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |